To facilitate more CD34+ cells yield and additional anti-myeloma effects, CTX was combined with hematopoietic growth factors (like G-CSF or GM-CSF) as a common regimen for PBSC mobilization. This evidence concerns the gene CSF2 and plasma cell myeloma.